Covered recipient · General Payments record
JULIA MAYOTTE
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2024
$597.83
- Reported across 14 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $365.61 | 11 |
| Education | $232.22 | 3 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $157.23 | 2 |
| Genmab U.S., Inc. | $122.05 | 1 |
| Exelixis Inc. | $74.99 | 1 |
| ABBVIE INC. | $64.56 | 2 |
| Janssen Biotech, Inc. | $31.80 | 1 |
| UROGEN PHARMA, INC. | $26.41 | 1 |
| Stemline Therapeutics Inc. | $23.50 | 1 |
| Janssen Scientific Affairs, LLC | $22.03 | 1 |
| JAZZ PHARMACEUTICALS INC. | $21.05 | 1 |
| SANOFI-AVENTIS U.S. LLC | $20.36 | 1 |
| Merck Sharp & Dohme Corporation | $17.09 | 1 |
| Ipsen Biopharmaceuticals, Inc | $16.76 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2024 | $597.83 | 14 |
Payment records · PY2024 (14)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $33.69 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107613313 | CMS |
| ABBVIE INC. | $30.87 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107613315 | CMS |
| Exelixis Inc. | $74.99 | 09/06/2024 | Education | Undisputed | 01/23/2026 | 1138571393 | CMS |
| Genmab U.S., Inc. | $122.05 | 05/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126839897 | CMS |
| Ipsen Biopharmaceuticals, Inc | $16.76 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091986723 | CMS |
| Janssen Biotech, Inc. | $31.80 | 05/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078391497 | CMS |
| Janssen Scientific Affairs, LLC | $22.03 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078846583 | CMS |
| JAZZ PHARMACEUTICALS INC. | $21.05 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151312671 | CMS |
| Lilly USA, LLC | $100.54 | 06/25/2024 | Education | Undisputed | 01/23/2026 | 1135661189 | CMS |
| Lilly USA, LLC | $56.69 | 06/27/2024 | Education | Undisputed | 01/23/2026 | 1135701052 | CMS |
| Merck Sharp & Dohme LLC | $17.09 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141853275 | CMS |
| SANOFI-AVENTIS U.S. LLC | $20.36 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140013425 | CMS |
| Stemline Therapeutics Inc. | $23.50 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142968337 | CMS |
| UROGEN PHARMA, INC. | $26.41 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137923333 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2024
- Source files
- Dataset page · Bulk file · PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.